Cargando…

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3

With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations,...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Fouchardière, Christelle, Gamradt, Pia, Chabaud, Sylvie, Raddaz, Maxime, Blanc, Ellen, Msika, Olivier, Treilleux, Isabelle, Bachy, Sophie, Cattey-Javouhey, Anne, Guibert, Pierre, Sarabi, Matthieu, Rochefort, Pauline, Funk-Debleds, Pamela, Coutzac, Clélia, Ray-Coquard, Isabelle, Peyrat, Patrice, Meeus, Pierre, Rivoire, Michel, Dupré, Aurélien, Hennino, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/
https://www.ncbi.nlm.nih.gov/pubmed/35455739
http://dx.doi.org/10.3390/jpm12040623
_version_ 1784690907739586560
author de la Fouchardière, Christelle
Gamradt, Pia
Chabaud, Sylvie
Raddaz, Maxime
Blanc, Ellen
Msika, Olivier
Treilleux, Isabelle
Bachy, Sophie
Cattey-Javouhey, Anne
Guibert, Pierre
Sarabi, Matthieu
Rochefort, Pauline
Funk-Debleds, Pamela
Coutzac, Clélia
Ray-Coquard, Isabelle
Peyrat, Patrice
Meeus, Pierre
Rivoire, Michel
Dupré, Aurélien
Hennino, Ana
author_facet de la Fouchardière, Christelle
Gamradt, Pia
Chabaud, Sylvie
Raddaz, Maxime
Blanc, Ellen
Msika, Olivier
Treilleux, Isabelle
Bachy, Sophie
Cattey-Javouhey, Anne
Guibert, Pierre
Sarabi, Matthieu
Rochefort, Pauline
Funk-Debleds, Pamela
Coutzac, Clélia
Ray-Coquard, Isabelle
Peyrat, Patrice
Meeus, Pierre
Rivoire, Michel
Dupré, Aurélien
Hennino, Ana
author_sort de la Fouchardière, Christelle
collection PubMed
description With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations, PDAC has not yet benefited from the recent therapeutic advances that immune checkpoint inhibitors (ICI) have provided in other cancer types, except in specific subgroups of patients presenting with tumors with high mutational burden (TMB) or microsatellite instability (MSI). The tumor microenvironment (TME) plays a substantial role in therapeutic resistance by facilitating immune evasion. An extracellular stromal protein, βig-h3/TGFβi, is involved in the pathogenesis of PDAC by hampering T cell activation and promoting stiffness of the TME. The study BIGHPANC included 41 patients with metastatic PDAC, and analyzed βig-h3 levels in serum and tumor samples to assess the βig-h3 prognostic value. βig-h3 serum levels are significantly associated with overall survival (HR 2.05, 95%CI 1.07–3.93; p = 0.0301). Our results suggest that βig-h3 serum levels may be considered a prognostic biomarker in patients with metastatic PDAC.
format Online
Article
Text
id pubmed-9025577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90255772022-04-23 A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 de la Fouchardière, Christelle Gamradt, Pia Chabaud, Sylvie Raddaz, Maxime Blanc, Ellen Msika, Olivier Treilleux, Isabelle Bachy, Sophie Cattey-Javouhey, Anne Guibert, Pierre Sarabi, Matthieu Rochefort, Pauline Funk-Debleds, Pamela Coutzac, Clélia Ray-Coquard, Isabelle Peyrat, Patrice Meeus, Pierre Rivoire, Michel Dupré, Aurélien Hennino, Ana J Pers Med Article With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations, PDAC has not yet benefited from the recent therapeutic advances that immune checkpoint inhibitors (ICI) have provided in other cancer types, except in specific subgroups of patients presenting with tumors with high mutational burden (TMB) or microsatellite instability (MSI). The tumor microenvironment (TME) plays a substantial role in therapeutic resistance by facilitating immune evasion. An extracellular stromal protein, βig-h3/TGFβi, is involved in the pathogenesis of PDAC by hampering T cell activation and promoting stiffness of the TME. The study BIGHPANC included 41 patients with metastatic PDAC, and analyzed βig-h3 levels in serum and tumor samples to assess the βig-h3 prognostic value. βig-h3 serum levels are significantly associated with overall survival (HR 2.05, 95%CI 1.07–3.93; p = 0.0301). Our results suggest that βig-h3 serum levels may be considered a prognostic biomarker in patients with metastatic PDAC. MDPI 2022-04-12 /pmc/articles/PMC9025577/ /pubmed/35455739 http://dx.doi.org/10.3390/jpm12040623 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
de la Fouchardière, Christelle
Gamradt, Pia
Chabaud, Sylvie
Raddaz, Maxime
Blanc, Ellen
Msika, Olivier
Treilleux, Isabelle
Bachy, Sophie
Cattey-Javouhey, Anne
Guibert, Pierre
Sarabi, Matthieu
Rochefort, Pauline
Funk-Debleds, Pamela
Coutzac, Clélia
Ray-Coquard, Isabelle
Peyrat, Patrice
Meeus, Pierre
Rivoire, Michel
Dupré, Aurélien
Hennino, Ana
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
title A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
title_full A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
title_fullStr A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
title_full_unstemmed A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
title_short A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
title_sort promising biomarker and therapeutic target in patients with advanced pdac: the stromal protein βig-h3
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/
https://www.ncbi.nlm.nih.gov/pubmed/35455739
http://dx.doi.org/10.3390/jpm12040623
work_keys_str_mv AT delafouchardierechristelle apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT gamradtpia apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT chabaudsylvie apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT raddazmaxime apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT blancellen apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT msikaolivier apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT treilleuxisabelle apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT bachysophie apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT catteyjavouheyanne apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT guibertpierre apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT sarabimatthieu apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT rochefortpauline apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT funkdebledspamela apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT coutzacclelia apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT raycoquardisabelle apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT peyratpatrice apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT meeuspierre apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT rivoiremichel apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT dupreaurelien apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT henninoana apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT delafouchardierechristelle promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT gamradtpia promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT chabaudsylvie promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT raddazmaxime promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT blancellen promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT msikaolivier promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT treilleuxisabelle promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT bachysophie promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT catteyjavouheyanne promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT guibertpierre promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT sarabimatthieu promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT rochefortpauline promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT funkdebledspamela promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT coutzacclelia promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT raycoquardisabelle promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT peyratpatrice promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT meeuspierre promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT rivoiremichel promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT dupreaurelien promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3
AT henninoana promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3